<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342365</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2017/JPL-01</org_study_id>
    <nct_id>NCT03342365</nct_id>
  </id_info>
  <brief_title>Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology</brief_title>
  <acronym>TRANSNEUTROFEB</acronym>
  <official_title>Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to study intestinal bacterial and fungal translocation and the
      evolution of the intestinal microbiota in patients over the course of their medical
      surveillance to search for a link between dysbiosis and bacterial/fungal translocation, but
      also to better understand the elements involved in febrile episodes in these patients (lack
      of detection of blood microorganisms, translocation of constituent elements of these
      microorganisms, etc.). We hypothesize that the composition of the intestinal microbiota as
      well as the phenomenon of intestinal microbial translocation will have an influence on the
      occurrence of fever and/or bacteremia in neutropenic patients hospitalized in pediatric
      onco-hematology.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of presence of bacterial and fungal translocation on occurrence of episodes of febrile neutropenia in pediatric onco-hematology patients.</measure>
    <time_frame>Between day 7-15</time_frame>
    <description>Presence or absence of microbial translocation; presence = ≥ 10 copies of rDNA16S/µL and/or ≥ 1 copies rDNA 18S/µL and ≥10 ng/mL LBP, ≥10 ng/mL of sCD14 and ≥5 ng/mL of zonulin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate prognostic quality of fungal and bacterial translocation markers in occurrence of episodes of febrile neutropenia of unknown origin</measure>
    <time_frame>Between day 7-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate prognostic quality of fungal and bacterial translocation markers in occurrence of episodes of febrile neutropenia in bacteremic patients</measure>
    <time_frame>Between day 7-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare bacterial and fungal translocation kinetics in febrile neutropenic patients of unknown origin versus bacteremic patients</measure>
    <time_frame>Between day 7-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare direct (16S rDNA, 18S rDNA) versus indirect (LBP, sCD14 and plasma zonulin) measures of translocation and association with bioclinical characteristics of the population</measure>
    <time_frame>Between day 7-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the kinetics of markers and intestinal microbial phylogenetic compositions according to the bioclinical characteristics of the population</measure>
    <time_frame>Between day 7-15</time_frame>
    <description>Diversity defined by number of different species and number of different taxonomic groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creation of biobank</measure>
    <time_frame>end of study day 30</time_frame>
    <description>All blood and stool samples taken from patients who develop neutropenia. Patients who do not develop neutropenia will have their samples collected at inclusion destroyed</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Febrile Neutropenia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Evaluation of microbial translocation and microbiota</intervention_name>
    <description>Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the CHU Nîmes onco-pediatric service with febrile neutropenia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Information concerning the study set-up, objectives, constraints and the
                  patient's rights is transmitted

               -  The patient and/or their legal guardian must have given their free and informed
                  consent. If the patient is over 18, it is the patient who signs the consent form

               -  The patient must be a member or beneficiary of a health insurance plan

          -  Exclusion Criteria:

               -  The patient is under state guardianship or safeguard of justice

               -  Refusal to sign the consent

               -  It is impossible to give the subject informed information

               -  Pregnant, parturient or breast feeding patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Lavigne</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe Lavigne</last_name>
    <phone>04.66.68.32.02</phone>
    <email>jean.philippe.lavigne@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UFR de Pharmacie Laboratoire de Parasitologie et Mycologie Médicale</name>
      <address>
        <city>Montpellier</city>
        <zip>34093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>342995</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Lavigne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quentin Chevrier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine Lavigne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Dunyach-Remy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Marchandin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

